Heart transplant patients admitted to the hospital with COVID-19 symptoms may be sicker than nontransplant patients, but they present with the same symptoms as the general population.
Heart transplant with or without bridge to transplant LVAD therapy was found to be associated with greater 5-year survival compared with LVAD destination therapy in patients with end-stage heart failure.
The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.
